Ligand Pharmaceuticals LGND EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Ligand Pharmaceuticals’s reported figures.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's EBITDA?
- Ligand Pharmaceuticals (LGND) reported EBITDA of $25.58M in Q1 2026.
- How has Ligand Pharmaceuticals's EBITDA changed year-over-year?
- Ligand Pharmaceuticals's EBITDA increased by 193.2% year-over-year, from -$27.45M to $25.58M.
- What is the long-term trend for Ligand Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's EBITDA has grown at a -16.6% compound annual growth rate (CAGR), from $154.92M to $74.78M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.